Clin2
NCT07353294Possibly a fitEnrolling by invitation

Propranolol plus immunotherapy and chemo before bladder cancer surgery

Bladder Urothelial CarcinomaLymph Node Metastasis

Treatments studied

Part of Cancer clinical trials.

This trial tests adding a blood pressure medication (propranolol) to a combination of immunotherapy (tislelizumab) and chemotherapy before surgery for bladder cancer that has spread to lymph nodes. It aims to see if this can help shrink the tumor before it is removed.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
12 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You have bladder cancer (urothelial type) that has spread to nearby lymph nodes but not to other organs.
  • You are 18 or older and willing to follow the study plan.
  • You are able to do normal daily activities (ECOG score 0 or 1) or have reasons you cannot take standard cisplatin chemotherapy.
  • Your blood pressure is normal (between 110-140 systolic) without using blood pressure medicine.
  • You have not had prior treatment with immunotherapy drugs (like PD-1 or PD-L1 inhibitors) or other similar therapies.
  • You are not currently taking beta-blocker medication (like atenolol or metoprolol) or can safely stop it.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT04861584Recruiting· Phase 2
Immunotherapy plus chemo before bladder surgery for advanced cancer

This trial studies giving toripalimab (an immunotherapy) together with gemcitabine and cisplatin before bladder surgery. It aims to shrink locally advanced bladder cancer and make surgery more effective by using the immune system and chemotherapy together.

Guangzhou, Guangdong
NCT06364904Not yet recruiting· Phase 3
Immunotherapy plus chemo for advanced bladder cancer

This trial tests a new combination of immunotherapy (tislelizumab) plus chemotherapy (cisplatin and gemcitabine) with or without an extra drug (trilaciclib) for people with advanced bladder cancer that hasn't been treated yet. The goal is to see if this combination is safe and helps shrink tumors.

Guangzhou, Guangdong
NCT06364956Recruiting· Phase 1/Phase 2
Testing new drug combo for bladder cancer before surgery

This trial tests a combination of two drugs (Tislelizumab and Palbociclib) given before bladder removal surgery. It is for people with bladder cancer that has a specific genetic change and who cannot take the standard chemotherapy cisplatin.

Guangzhou, Guangdong
NCT07314723Recruiting· Phase 2
New drug combo before & after surgery for bladder cancer

This trial tests a new combination of two drugs—9MW2821 (an antibody-drug conjugate) and Toripalimab (an immunotherapy)—given before and after surgery for muscle-invasive or high-risk urothelial cancer that has not spread. The goal is to see if this combined treatment can improve outcomes.

Guangzhou, Guangdong
NCT07727993Not yet recruiting· Phase 1/Phase 2
Propranolol plus chemotherapy and immunotherapy before stomach cancer surgery

This trial tests adding a blood pressure medicine (propranolol) to standard chemotherapy and immunotherapy before surgery for locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this combination helps shrink the tumor and improve outcomes.

NCT06091124Recruiting· Phase 2
Immunotherapy plus chemo before surgery for neuroendocrine bladder cancer

This trial tests a combination of an immunotherapy drug (adebrelimab) with two chemotherapy drugs (etoposide and cisplatin) given before surgery for a rare, aggressive type of bladder cancer called neuroendocrine carcinoma. The goal is to see if this approach can shrink the tumor and improve outcomes.

Nanjing, Jiangsu

Hear when a new Lymph Node Metastasis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.